EC's open-access move threatens science publishers; EMA accepts laquinimod MS app; Clovis and Array ink new collaboration;

NEW! Conversations on  Twitter :

 @FierceBiotech: DeCode, Genentech find gene mutation marks protection against ‪Alzheimer's‬. More | Follow @FierceBiotech

 @JohnCFierce: Elan is priced for a buyout deal? Oh, my. Who would buy that company just now? Report | Follow @JohnCFierce

 @RyanMFierce: Alnylam up 45% after ALN-TTR02 passes Phase I. Could this be the RNAi drug we've all been waiting for? | Follow @RyanMFierce

> The lucrative business of publishing research papers is about to encounter a serious threat. The European Commission is moving to make all publicly-funded research studies freely available, spurring on an open-access movement that could torpedo the business model of publishers like Reed Elsevier, according to a report from Reuters' Ben Hirschler. Report

> Teva and Active Biotech say that the EMA has accepted their application for the MS drug laquinimod. Active won a $5M milestone based on the regulators' acceptance of the app for review. Release

> Clovis Oncology and Array BioPharma announced an agreement for the discovery of a novel KIT inhibitor targeting resistance mutations for the treatment of GIST. Release

> Ziopharm Oncology has announced a new executive team. Release

Pharma News

 @FiercePharma: Simponi‬ for colitis, J&J says: Janssen unit asks FDA to OK new use for Remicade follow-up drug. More | Follow @FiercePharma

> J&J drug sales hold their own, thanks to foreign growth. Report

> AZ puts Brilinta up for another head-to-head fight with Plavix. Article

> Appeals court ruling threatens pay-to-delay deals. News

> Par could fetch up to $2.5B from rival genericsmaker. More

Medical Device News

@FierceMedDev: Radiology devicemaker Accuray is buying Morhpormics for $5.7M. Release | Follow @FierceMedDev

@DamianFierce: Biomet has cut back its year-over-year losses due to sales growth in its major divisions. More | Follow @DamianFierce

> Life Technologies expands its Dx business with Navigenics buy. News

> J&J posts flat device sales for Q2. Article

> Ex-Medtronic CEO pulled down $8M in 2012. Story

Pharma Manufacturing News

> Lonza seeks growth in China after securing IP. Story

> Feds get conviction in fake J&J test strips case. More

> India regulator orders Aurobindo, others to close 12 plants. Report

> Hospira blames supplier's bad vials for latest recall. Article

Biotech Research News

> Researchers use gene therapy to treat spinal muscular atrophy. Article

> New 'molecular grenade' used to attack tumor cells. Report

> Researcher rebuts rival finding that ovarian stem cells exist. Story

> Rare gene mutation protects against Alzheimer's. More

> Alnylam generates preclinical buzz with RNAi hemophilia drug. News

And Finally… Some chocolate products may soon come with a label explaining how they can improve blood circulation. Story

 

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.